The global landscape of metabolic medicine is currently defined by a high-stakes race for dominance in the obesity and diabetes markets. This week, the European Association for the Study of Diabetes (EASD) held its annual meeting in Milan, serving as the industry’s most critical stage for pharmaceutical giants and emerging innovators to present data that could reshape the standard of care for millions.
While Eli Lilly and Novo Nordisk continue to command the market with their blockbuster therapies—Zepbound and Wegovy, respectively—the mood in Milan was not one of complacency. Instead, the focus has shifted toward the "next generation" of weight-loss treatments. As the medical community looks beyond basic GLP-1 receptor agonists, the conversation has pivoted toward maximizing weight loss, improving tolerability, and enhancing the convenience of delivery systems.
Main Facts: The Shifting Weight-Loss Paradigm
The current pharmaceutical gold rush in obesity is no longer just about efficacy; it is about differentiation. With billions of dollars in monthly revenue flowing into the coffers of market leaders, the pressure is mounting to provide solutions that address the "ceiling" of current treatments.
The primary takeaways from the EASD meeting include:
- Combination Therapies: The industry is moving toward multi-hormonal approaches, specifically targeting amylin alongside GLP-1, to potentially unlock deeper weight loss.
- The Oral Transition: Novo Nordisk is aggressively testing the transition from injectable therapies to oral tablets to increase patient adherence and comfort.
- Challenger Strategies: Companies like Boehringer Ingelheim and AbbVie are leveraging partnerships to enter the space with unique mechanisms of action, such as long-acting amylin analogs that promise less frequent dosing.
- Refining Patient Care: The data presented suggests a future where treatment is tiered, with some drugs serving as foundational, "softer" options, while others act as potent "heavy hitters" for those with the most significant clinical needs.
Chronology: A Rapidly Evolving Field
The evolution of these treatments has been nothing short of meteoric. To understand the gravity of the data presented in Milan, one must look at the recent timeline of metabolic breakthroughs:
- Early 2024: The massive market success of Wegovy and Zepbound creates a "super-cycle" in the pharmaceutical industry, prompting record-breaking investment in R&D.
- May 2026: Eli Lilly’s "triple-G" drug, retatrutide, sends shockwaves through the investor community with phase 3 data showing industry-leading weight loss potential.
- Late 2026 (EASD Milan): The spotlight turns to secondary strategies, specifically the use of amylin as a synergistic partner to existing GLP-1 therapies.
- Ongoing: Partnerships (e.g., AbbVie/Gubra, Boehringer/Zealand) come to fruition, as clinical trials move from early-phase safety studies to demonstrating tangible weight loss results in complex, multi-morbid patient populations.
Supporting Data: The Science Behind the Headlines
The data presented at EASD provides a granular look at the efficacy of these experimental compounds.
Eli Lilly’s Amylin-Zepbound Synergy
Lilly is doubling down on its flagship molecule, tirzepatide (Zepbound), by pairing it with eloralintide, an amylin-mimetic hormone. In a Phase 2 trial, the results were striking: patients with obesity who received the combination therapy for 48 weeks achieved a 23% reduction in body weight (approximately 54 pounds). For comparison, the high-dose Zepbound monotherapy resulted in 15% weight loss, while eloralintide alone achieved 12%.
Analysts are bullish on this approach. David Risinger of Leerink Research projects that eloralintide could reach $23 billion in annual sales by 2035. The clinical strategy, as suggested by Evercore ISI’s Umer Raffat, may eventually involve a tiered dosing regimen: starting patients on the more tolerable amylin-based monotherapy and escalating to the combination only if more aggressive weight loss is clinically required.
Novo Nordisk’s "Real-World" Oral Pivot
Novo Nordisk is focusing on patient experience. By collaborating with the direct-to-consumer platform Ro, the company tracked patients who transitioned from injectable Wegovy or Zepbound to an experimental oral form of its drug. The study found that patients maintained or improved their trajectory, losing an additional 4.1% of their body weight on average. Perhaps most significantly, the proportion of participants classified as clinically obese dropped from 87% to 66% following the transition.
Boehringer Ingelheim and AbbVie’s Emerging Profiles
Boehringer Ingelheim, in partnership with Zealand Pharma, presented data on survodutide—a dual GLP-1/glucagon agonist. In a trial focusing on patients with both obesity and type 2 diabetes—a demographic traditionally harder to treat—patients saw a 13% average weight loss, a significant improvement over the 3% seen in the placebo group.
AbbVie is taking a different approach with ABBV-295, a long-acting amylin analog licensed from Gubra. Their goal is to maximize convenience. In a Phase 1 study, once-weekly, every-other-week, and even monthly dosing regimens were tested. While patients on the monthly regimen lost 8% of their body weight, the study also provided critical insights into the side-effect profile, with nausea reported at higher rates in the treatment group compared to the placebo, a common hurdle for this class of medicine.
Official Responses and Clinical Perspectives
The medical community is cautiously optimistic about these developments. Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, highlighted the clinical value of the oral data presented by Novo Nordisk. "These are exciting early insights on how the pill can individualize obesity care," Aronne stated. "We look forward to seeing longer-term outcomes to understand how this fits into the broader chronic management of obesity."
Industry experts emphasize that the next phase of this market will be defined by "tolerability." William Blair analyst Andy Hsieh noted that the inclusion of amylin-targeting drugs, such as petrelintide and cagrilintide, could provide a "softer" landing for patients who struggle with the intense gastrointestinal side effects often associated with current GLP-1 therapies.
Implications: The Future of Metabolic Medicine
The implications of the data presented in Milan are far-reaching, both for the pharmaceutical industry and the global healthcare system.
1. The End of "One-Size-Fits-All" Treatment
The shift toward multi-hormonal and long-acting therapies suggests that clinicians will soon have a "toolbox" of options rather than a single blockbuster drug. We are entering an era of precision metabolic medicine where physicians can tailor treatments based on a patient’s specific side-effect tolerance and weight-loss goals.
2. The Economic Moat
For incumbents like Lilly and Novo Nordisk, the strategy is clearly to build an "economic moat" around their existing products. By creating proprietary combinations (like Lilly’s Zepbound/eloralintide) or improving delivery methods (like Novo’s oral pill), they are effectively raising the barrier to entry for generic competitors and smaller biotech firms.
3. Addressing the Chronic Nature of Obesity
The data from the AbbVie trial, specifically the pursuit of monthly injections, signals that the industry is beginning to treat obesity as a lifelong chronic condition rather than a temporary fix. Improving the convenience of administration is a prerequisite for long-term patient compliance.
4. The Challenge of Cost and Access
While the scientific innovation is impressive, the implications for healthcare systems remain complex. As drugmakers introduce increasingly sophisticated (and likely more expensive) combination therapies, the burden on public and private insurance systems will intensify. The focus of the next few years will inevitably shift from "does this work?" to "how do we pay for it at scale?"
As the EASD meeting in Milan concludes, one thing is clear: the obesity drug market is no longer a sprint; it is a marathon of innovation. With billions in capital flowing toward the next generation of treatments, the battle for the hearts, minds, and prescriptions of the global medical community has only just begun. The companies that can balance clinical efficacy with the "real-world" needs of convenience and tolerability will be the ones to define the next decade of metabolic health.
About the Author
